Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis (Q35369413)

8 August 2017

Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis (English)

1 reference

8 August 2017

1 reference

2

Marc R Laufer

1 reference

8 August 2017

Amy D Divasta

1

1 reference

PubMed ID

17868896

8 August 2017

Catherine M Gordon

series ordinal

3

1 reference

8 August 2017

1 October 2007

1 reference

Journal of Pediatric and Adolescent Gynecology

8 August 2017

1 reference

8 August 2017

20

1 reference

8 August 2017

5

1 reference

8 August 2017

293-297

1 reference

Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up

8 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195423

Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195423

Proximal femur bone mineral levels of US adults

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195423

Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. Inference from a cross-sectional model

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195423

Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195423

One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195423

Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195423

Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195423

ACOG Committee Opinion. Number 310, April 2005. Endometriosis in adolescents

26 September 2018

1 reference

12 December 2020

Evidence that the loss of bone mass induced by GnRH agonists is not totally recovered

1 reference

12 December 2020

Should add-back therapy for endometriosis be deferred for optimal results?

1 reference

12 December 2020

Retreatment with nafarelin for recurrent endometriosis symptoms: efficacy, safety, and bone mineral density

1 reference

12 December 2020

Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy

1 reference

12 December 2020

Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group

1 reference

12 December 2020

The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover

1 reference

12 December 2020

10.1016/J.JPAG.2007.04.008

Identifiers

DOI

1 reference

8 August 2017

1 reference

8 August 2017

1 reference

PubMed ID

17868896